Evolving Role of Biologics: A Payer’s and Provider’s Perspective

Supplements
Download PDF
Gary Rice, RPh, MS, MBA

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: April 29th, 2011 - April 29th, 2012

Target Audience
This activity was developed for pharmacists and other healthcare professionals practicing in a managed care environment.

Learning Objectives
Upon completion of this activity, the participant will be able to:

  • Provide payers with a practical understanding of the key clinical, business, and regulatory factors, guidelines, and research advances involving healthcare policy with respect to biologics in the treatment of chronic diseases that providers are using as the basis for their treatment decisions
  • Offer payers a multi-stakeholder commentary on this information to identify the impact of these changes to treatment on different stakeholders
  • Illuminate the different perspectives and incentives of the various stakeholders involved in biologic treatment decisions, including patients, providers, payers, purchasers, distributors, regulatory agencies, and manufacturers
  • Align incentives with providers and transform payer drug management policies into patient-centered, value-based models

Pharmacists’ Designation
Medical Learning Institute, Inc., is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-11-018-H01-P.

Disclosures
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity for any amount during the past 12 months.

Planners’ and Managers’ Disclosures
Teresa Haile, RPh, MBA, is the MLI reviewer and has nothing to disclose.

Faculty Disclosures
Gary Rice, RPh, MS, MBA, has nothing to disclose.
Loretta Fala, medical writer, has stock ownership at Micronet.

Disclaimer
The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Estimated time to complete activity: 1 hour

Related Items
NCCN Updated Guidelines for Breast Cancer: A Payer's Perspective
Gary Rice, RPh, MS, MBA
Supplements published on August 14, 2009
Value-Based Oncology Benefit Design™ Balancing Cost, Quality, and Access in Cancer Care
Gary M. Owens, MD, Al B. Benson III, MD, FACP, Gary Rice, RPh, MS, MBA
Supplements published on June 30, 2009
Last modified: March 21, 2014